Tag: Sexually Transmitted Diseases: AIDS/HIV
Dolutegravir-Based ART Superior for Children, Teens With HIV
Rate of serious adverse events similar for participants receiving dolutegravir, standard care as first-, second-line treatment for HIV-1 infection
First Long-Acting Injectable Approved for HIV PrEP
Apretude, administered every two months, is approved in adults and adolescents at risk for HIV infection
Pediatricians Can Play Key Role in HIV Testing, Prophylaxis
All youth ages 15 years or older should be offered routine screening at least once; those at increased risk should be rescreened
Number of Older People With HIV on ART Projected to Increase
Simulation model of people with HIV using ART in the U.S. projects increase in overall median age from 50 years in 2020 to 52 years in 2030
WHO Approves First Long-Acting Device to Shield Women From HIV
Vaginal ring made of silicone elastomer releases antiretroviral drug dapivirine into the vagina slowly over 28 days
Biden’s New HIV/AIDS Strategy Calls Racism a Roadblock to Victory
Strategy outlines the direction of the White House's policies, research, programs, and planning for the next three years
Some High-Priority Groups More Likely to Stop Taking PrEP
Younger individuals, African American and Latinx, those with substance use disorders more likely to discontinue PrEP
Among Persons With HIV, More Finish Short-Course TB Prophylaxis
Treatment completion 90.4 percent for three months of rifapentine-isoniazid versus 50.5 percent for six months of isoniazid
Cabotegravir Bests TDF-FTC for HIV Prevention in Those at Risk
Long-acting injectable cabotegravir superior for preventing HIV infection in men who have sex with men, transgender women
PrEP HIV Prevention Pills to Be Free for Insured Americans
HIV prevention advocates say the new guidance is a game changer
